Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations

Ming Mo Hou; Shiu Feng Huang; Han Pin Kuo; Cheng T.A. Yang; Ying Huang Tsai; Chih Teng Yu; Horng Chyuan Lin; Chih Hung Chen; Chih Liang Wang; Fu Tsai Chung; Jia Juan Hsieh; Todd Hsu; Hsin Yi Cheng; Li Ying Ou; Hung Ming Wang; Yung Chang Lin; Nai Jen Chang; John Wen Cheng Chang

Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations

Ming Mo Hou, Shiu Feng Huang, Han Pin Kuo, Cheng T.A. Yang, Ying Huang Tsai, Chih Teng Yu, Horng Chyuan Lin, Chih Hung Chen, Chih Liang Wang, Fu Tsai Chung, Jia Juan Hsieh, Todd Hsu, Hsin Yi Cheng, Li Ying Ou, Hung Ming Wang, Yung Chang Lin, Nai Jen Chang, John Wen Cheng Chang

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background: Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib. Patients and Methods: Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed. Results: Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups. Conclusion: EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.

Original language	English
Pages (from-to)	1107-1112
Number of pages	6
Journal	Anticancer Research
Volume	32
Issue number	3
Publication status	Published - Mar 1 2012
Externally published	Yes

Keywords

Adenocarcinoma
Chromogenic in situ hybridization (CISH)
EGFR
Erlotinib
Lung cancer

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hou, M. M., Huang, S. F., Kuo, H. P., Yang, C. T. A., Tsai, Y. H., Yu, C. T., Lin, H. C., Chen, C. H., Wang, C. L., Chung, F. T., Hsieh, J. J., Hsu, T., Cheng, H. Y., Ou, L. Y., Wang, H. M., Lin, Y. C., Chang, N. J., & Chang, J. W. C. (2012). Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations. Anticancer Research, 32(3), 1107-1112.

@article{2f2de6ed2d1a4b11a7eceeda7437cf5e,

title = "Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations",

abstract = "Background: Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib. Patients and Methods: Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed. Results: Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups. Conclusion: EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.",

keywords = "Adenocarcinoma, Chromogenic in situ hybridization (CISH), EGFR, Erlotinib, Lung cancer",

author = "Hou, {Ming Mo} and Huang, {Shiu Feng} and Kuo, {Han Pin} and Yang, {Cheng T.A.} and Tsai, {Ying Huang} and Yu, {Chih Teng} and Lin, {Horng Chyuan} and Chen, {Chih Hung} and Wang, {Chih Liang} and Chung, {Fu Tsai} and Hsieh, {Jia Juan} and Todd Hsu and Cheng, {Hsin Yi} and Ou, {Li Ying} and Wang, {Hung Ming} and Lin, {Yung Chang} and Chang, {Nai Jen} and Chang, {John Wen Cheng}",

year = "2012",

month = mar,

day = "1",

language = "English",

volume = "32",

pages = "1107--1112",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations

AU - Hou, Ming Mo

AU - Huang, Shiu Feng

AU - Kuo, Han Pin

AU - Yang, Cheng T.A.

AU - Tsai, Ying Huang

AU - Yu, Chih Teng

AU - Lin, Horng Chyuan

AU - Chen, Chih Hung

AU - Wang, Chih Liang

AU - Chung, Fu Tsai

AU - Hsieh, Jia Juan

AU - Hsu, Todd

AU - Cheng, Hsin Yi

AU - Ou, Li Ying

AU - Wang, Hung Ming

AU - Lin, Yung Chang

AU - Chang, Nai Jen

AU - Chang, John Wen Cheng

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Background: Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib. Patients and Methods: Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed. Results: Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups. Conclusion: EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.

AB - Background: Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib. Patients and Methods: Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed. Results: Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups. Conclusion: EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.

KW - Adenocarcinoma

KW - Chromogenic in situ hybridization (CISH)

KW - EGFR

KW - Erlotinib

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84863345190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863345190&partnerID=8YFLogxK

M3 - Article

C2 - 22399641

AN - SCOPUS:84863345190

SN - 0250-7005

VL - 32

SP - 1107

EP - 1112

JO - Anticancer Research

JF - Anticancer Research

IS - 3

ER -

Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this